Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

80.60 -1.18 (-1.44%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,887,392
Open	81.18
Bid (Size)	80.58 (4,700)
Ask (Size)	80.73 (4,600)
Prev. Close	81.78
Today's Range	79.78 - 82.56
52wk Range	23.95 - 86.74
Shares Outstanding	141,797,854
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Alnylam Pharmaceuticals (ALNY): The RNAi Pioneer’s 2026 Breakout and the Battle for Cardiovascular Dominance

February 12, 2026

As of February 12, 2026, Alnylam Pharmaceuticals (NASDAQ: ALNY) has officially transcended its status as a high-potential biotech and entered the pantheon of global pharmaceutical powerhouses. Known as...

Via Finterra

Ionis to hold fourth quarter and full year 2025 financial results webcast

February 11, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Performance

YTD	+1.2%	+1.2%
1 Month	+1.4%	+1.4%
3 Month	+15.4%	+15.4%
6 Month	+88.1%	+88.1%
1 Year	+161.3%	+161.3%

More News

Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy

February 04, 2026

From Biogen Inc.

Via GlobeNewswire

IONIS PHARMACEUTICALS INC (NASDAQ:IONS) Shows High-Quality Technical Breakout Setup ↗

January 23, 2026

Via Chartmill

What a $20 Million Bet on a Stock Down 3% Signals for Investors ↗

February 03, 2026

Via The Motley Fool

Autoliv Stock Is Up 32% in a Year, But One Fund Just Cut $3.8 Million ↗

February 03, 2026

Via The Motley Fool

DAWNZERA™ (donidalorsen) approved in the European Union for hereditary angioedema (HAE)

January 21, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy

January 12, 2026

From Biogen Inc.

Via GlobeNewswire

Ionis well-positioned for continued momentum and substantial value creation in 2026 with two new independent launches and several pivotal data readouts

January 12, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B

January 07, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis to present at 44th Annual J.P. Morgan Healthcare Conference

January 06, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

The RNAi Powerhouse: A Deep Dive into Alnylam Pharmaceuticals’ Path to the S&P 500

January 02, 2026

Via PredictStreet

Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD)

December 02, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis receives U.S. FDA Breakthrough Therapy designation for olezarsen for severe hypertriglyceridemia (sHTG)

December 01, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy

November 17, 2025

From Biogen Inc.

Via GlobeNewswire

Biogen Completes Acquisition of Alcyone Therapeutics

November 14, 2025

From Biogen Inc.

Via GlobeNewswire

DAWNZERA™ (donidalorsen) receives positive opinion from CHMP, recommended for approval in EU for hereditary angioedema (HAE)

November 14, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis Prices Convertible Notes Offering to Refinance 2026 Convertible Notes

November 13, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis to present at upcoming investor conferences

November 12, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Metagenomi Prioritizes Hemophilia A Program, Lays Off 25% Workforce ↗

November 12, 2025

Via Benzinga

Ionis Announces Proposed Convertible Offering to Refinance 2026 Convertible Notes

November 11, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis Reports Substantial Drop In Acute Pancreatitis Events With Cholesterol Lowering Drug ↗

November 10, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

November 10, 2025

Via Benzinga

Monday.Com, Metsera, Profrac Holding And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

November 10, 2025

Via Benzinga

Why Viasat Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket ↗

November 10, 2025

Via Benzinga

Frequently Asked Questions

Is Ionis Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, Ionis Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does Ionis Pharmaceuticals, Inc. - Common Stock trade on?

Ionis Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Ionis Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for Ionis Pharmaceuticals, Inc. - Common Stock is IONS on the Nasdaq Stock Market

What is the current price of Ionis Pharmaceuticals, Inc. - Common Stock?

The current price of Ionis Pharmaceuticals, Inc. - Common Stock is 80.60

When was Ionis Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of Ionis Pharmaceuticals, Inc. - Common Stock was at 02/13/26 04:00 PM ET

What is the market capitalization of Ionis Pharmaceuticals, Inc. - Common Stock?

The market capitalization of Ionis Pharmaceuticals, Inc. - Common Stock is 11.43B

How many shares of Ionis Pharmaceuticals, Inc. - Common Stock are outstanding?

Ionis Pharmaceuticals, Inc. - Common Stock has 11B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.